Juxtapid is a first-in-class treatment for adult patients with HoFH.* This section covers a range of information regarding the steps to take before you start a patient on Juxtapid, dosing & administration, and patient monitoring.
Because of the risk of hepatotoxicity, Juxtapid is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the JUXTAPID REMS Program. For complete information on the Program go to www.JUXTAPIDREMSProgram.com.
Juxtapid is contraindicated in the following conditions:
- Concomitant administration of moderate or strong CYP3A4 inhibitors
- Moderate or severe hepatic impairment or active liver disease including unexplained persistent elevations of serum transaminases.